Clover Health (CLOV) Q1 2026 earnings review
The Flywheel Engages: Massive Top-Line Surge and a Swing to Profitability
Clover Health's Q1 2026 results confirm management's multi-year narrative: the 'growth flywheel' has been activated. Fueled by a lucrative transition to a 4-Star payment year and aggressive prior-year member acquisition, total revenues accelerated by 62% YoY to $749.2M. More importantly, the company posted its highest GAAP Net Income to date at $27.3M, a dramatic reversing of historical losses. While the top-line execution and operating leverage are undeniably impressive, a glaring contradiction in guidance requires investor caution: the company expects FY26 GAAP Net Income of $0-$20M, implying that Q2-Q4 will operate at a net loss.
🐂 Bull Case
Membership grew 51% YoY to over 155,000, and revenue growth accelerated to 62% YoY. Clover is aggressively taking market share in the PPO space as competitors retreat.
The long-awaited 4-Star payment tailwind and the maturation of the 2025 member cohort have successfully flipped the company to GAAP profitability, yielding $27.3M in Q1.
🐻 Bear Case
With Q1 Net Income at $27.3M and FY26 guided to $0-$20M, the company implies it will lose between $7.3M and $27.3M over the next three quarters. The profit narrative is highly front-loaded.
The Insurance Benefits Expense Ratio (BER) ticked up 40 bps YoY to 86.5%. Despite the massive 4-Star revenue boost, medical costs continue to consume a slightly larger portion of premiums.
⚖️ Verdict: 🟢
Bullish. The sheer velocity of revenue and membership growth, coupled with a swing to GAAP profitability, outweighs near-term seasonality concerns. Clover has proven its technology-first model can scale profitably.
Key Themes
The 4-Star Payment Catalyst Ignites
The transition from a 3.5-Star to a 4-Star payment year in 2026 is delivering exactly as management projected in 2025. This structural benchmark advantage allows Clover to offer highly competitive PPO benefits while simultaneously expanding margins. Total revenue growth is sharply accelerating, hitting 62% in Q1 compared to 30-40% levels seen throughout 2025.
Cohort Maturation Yields Returns
During 2025, management absorbed significant margin pressure (guiding down adjusted EBITDA) to fund a massive influx of new members, claiming they would become profitable in year two. Q1 2026 data validates this claim. The gross profit surge of 46.5% YoY proves that the initial drag of the 2025 cohort has successfully transitioned into a profitable returning member base.
SG&A Operating Leverage Realized
As the top-line explodes, Clover is keeping a tight lid on corporate overhead. Adjusted SG&A as a percentage of total revenues dropped 210 basis points YoY to 15.9%. This operational efficiency was the secondary mechanism necessary to swing Adjusted EBITDA up 56% to $40.3M.
The Q1 Profit Contradiction
A massive red flag sits in the guidance math. Management celebrates Q1 GAAP Net Income of $27.3M, yet guides for a full-year GAAP Net Income of $0 to $20M. This explicitly implies that Q2, Q3, and Q4 will generate a combined net loss. While some seasonality in healthcare utilization is normal, a potential $27M reversal in the back nine months suggests that management anticipates severe medical cost headwinds, or they are heavily sandbagging guidance.
Insurance BER Ticking Higher
Despite the structural revenue advantage of a 4-Star year, the Insurance Benefits Expense Ratio (BER) expanded 40 bps to 86.5%. While this remains within a stable operating band, it confirms that underlying systemic utilization pressures (such as Part D and supplemental benefits cited heavily in 2025) are persistently challenging to offset.
Counterpart Health Financial Obscurity
Management continues to pitch its 'Counterpart Assistant' SaaS offering as a massive blue-ocean opportunity to monetize its AI infrastructure with external payors. However, the Q1 2026 materials offer zero quantitative metrics—no ARR, no partner count, and no distinct segment breakout. Until the data arrives, this remains an unproven narrative.
Macro: Persistent Inflation & IRA Complexities
The company's forward-looking statements specifically call out 'persistent high inflation' and ongoing shifts in Medicare Advantage regulations. Given the lack of clarity on how the second year of the Part D IRA redesign will hit the industry, this macro backdrop helps explain management's highly conservative back-half profit guidance.
Clover Assistant: The Core Tech Differentiator
The fundamental engine of Clover's model—Clover Assistant—continues to prove its worth. Management attributes earlier disease identification, better chronic care management, and their market-leading PPO HEDIS scores entirely to this proprietary software platform.
Other KPIs
Accelerating. Up 56.2% year-over-year. A clear indication that core operations are scaling profitably after the heavy investments made in 2025.
Stable. Up 7.0% from Q1 2025 ($390.8M). The company is successfully self-funding its hyper-growth without deteriorating its balance sheet.
Guidance
Accelerating. The midpoint of $2.865B represents ~49% growth year-over-year compared to the ~$1.865B expected for FY25, highlighting the immense top-line impact of the 4-Star rating and continued market share capture.
Accelerating. Midpoint represents 46% year-over-year growth, up from the ~33% growth rate seen throughout 2025. Clover is aggressively capitalizing on competitor pullbacks.
Reversing. A significant leap compared to the heavily suppressed $15M-$30M guidance exiting 2025, driven by cohort maturation and 4-Star rates.
Reversing. Expected to be the first full year of GAAP profitability in company history. However, given Q1 delivered $27.3M, this guidance implies a dramatic deceleration and net losses for the remainder of the year.
Key Questions
The Implied Q2-Q4 Loss
With $27.3 million in Q1 GAAP Net Income, your full-year guidance of $0 to $20 million mathematically requires a net loss for the rest of the year. Is this purely conservative sandbagging, or do you expect specific, severe medical cost headwinds to materialize?
Counterpart Health Monetization
You've highlighted Counterpart Health as a massive growth vector. When will investors see specific KPIs like ARR, active partner counts, or a dedicated segment revenue breakout?
BER Margin Expansion
Despite a massive step-up in revenue from the 4-Star payment transition, the Insurance BER still ticked up by 40 basis points. What is driving the inability to leverage this higher premium revenue into a lower medical loss ratio?
Part D and IRA Impact
In 2025, the industry was caught off guard by Part D utilization related to IRA changes. How is the 2026 plan design and current utilization data insulating Clover from a repeat scenario?